• Facebook
  • X
  • Instagram
MYELOMA360
  • Home
  • MYInsights
  • MYBoard
  • Strategy & Consulting
Select Page

The Burst of Spring: Reflection for Those Living with Cancer

by MM360 Staff | Apr 23, 2025 | Uncategorized

Source: CureToday articles As spring arrives, I embrace the season’s renewal, reflecting on my journey with cancer and the freedom I’ll feel when I stop my treatment. Life is a gift. Read More

Ivonescimab Plus Chemo May Slow Advanced NSCLC Progression

by MM360 Staff | Apr 23, 2025 | Uncategorized

Source: CureToday articles Post Content Read More

FDA Grants Breakthrough Status to CAR-T Therapy for Pediatric Brain Tumor

by MM360 Staff | Apr 23, 2025 | Uncategorized

Source: CureToday articles The FDA granted breakthrough therapy designation to an autologous CAR-T cell therapy for pediatric patients with diffuse intrinsic pontine glioma. Read More

First Patient Dosed with AP402 in a Trial for HER2 Advanced Tumors

by MM360 Staff | Apr 23, 2025 | Uncategorized

Source: CureToday articles Post Content Read More

Advocacy and ‘Radiating Valor’ Have a Transformative Impact

by MM360 Staff | Apr 22, 2025 | Uncategorized

Source: CureToday articles Post Content Read More

LCI Launches Screening Saves Program

by MM360 Staff | Apr 22, 2025 | Uncategorized

Source: CureToday articles Post Content Read More
« Older Entries
Next Entries »

Recent Content

  • Safety and Efficacy of Bispecific Antibody Treatment in Relapsed/Refractory Multiple Myeloma: A Systematic Review and Meta-Analysis of Proportions from Clinical Trials
  • Increased risk of infections in smoldering multiple myeloma: results from the screened iStopMM study
  • Plasmapheresis facilitates soluble BCMA clearance and contributes to reversing primary resistance to anti-BCMA immunotherapy in multiple myeloma
  • Subcutaneous Darzalex Faspro Extends PFS in Smoldering Myeloma
  • A network meta-analysis of randomized clinical trials in lenalidomide-exposed or -refractory multiple myeloma patients
  • Subcutaneous Bortezomib Associated With Reduced Incidence of Peripheral Neuropathy in Multiple Myeloma
  • Multiple Myeloma: Key Insights on Diagnosis and Evolving Treatment Strategies
  • Multiple myeloma associated long non-coding RNA PLUM confers chemoresistance by enhancing PRC2 mediated UPR pathway activation
  • Mobilization of hematopoietic stem cells using G-CSF with or without cyclophosphamide before autologous stem cell transplantation in patients with newly diagnosed multiple myeloma receiving induction therapy with or without daratumumab
  • Incidence and prevalence of clinically detected smoldering multiple myeloma within the general population: a retrospective observational cohort study
  • Facebook
  • X
  • Instagram
©2016-2025 MYELOMA360 & Connect BioMed
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept”, you consent to the use of ALL the cookies.
Do not sell my personal information.
SettingsAccept
Privacy & Cookies Policy

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may have an effect on your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Non-necessary
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.
SAVE & ACCEPT